NBP Relieves Cardiac Injury and Reduce Oxidative Stress and Cell Apoptosis in Heart Failure Mice by Activating

Zhongyu Wang1, Yan Zhang2, Lei Wang3

  • 1Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130031, China.

Insights

Dl-3-n-butylphthalide (NBP) protects against heart failure by improving heart function and reducing myocardial injury in mice. This effect is linked to activating the Nrf2/HO-1 pathway and regulating calcium handling via SERCA2a.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure (HF) is a leading cause of mortality worldwide, with limited therapeutic options.
  • Oxidative stress and myocardial injury are key pathological features of HF.
  • Understanding novel therapeutic targets is crucial for improving HF treatment.

Purpose of the Study:

  • To investigate the protective effects of Dl-3-n-butylphthalide (NBP) on myocardial injury and oxidative stress in a mouse model of heart failure.
  • To elucidate the role of the Nrf2/HO-1/Ca2+-SERCA2a axis in NBP's cardioprotective mechanism.

Main Methods:

  • Established a heart failure mouse model using abdominal aorta ligation.
  • Assessed cardiac function via echocardiography and myocardial injury using histological staining (H&E, Masson) and TUNEL assay.
  • Quantified oxidative stress markers, Nrf2/HO-1 pathway proteins, Ca2+ influx, and SERCA2a levels using ELISA, immunofluorescence, and Western blotting.

Main Results:

  • NBP treatment significantly improved cardiac function, reduced myocardial injury, and inhibited apoptosis in HF mice.
  • NBP decreased endoplasmic reticulum stress (ERS) by increasing SERCA2a levels and reducing Ca2+ influx.
  • NBP minimized CaMKII phosphorylation and activated the Nrf2/HO-1 signaling pathway.

Conclusions:

  • NBP exhibits significant cardioprotective effects in a mouse model of heart failure.
  • NBP alleviates myocardial injury and endoplasmic reticulum stress by activating the Nrf2/HO-1 pathway and modulating Ca2+-SERCA2a signaling.
  • NBP represents a potential therapeutic agent for heart failure treatment.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
139
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19